Volume | 13,869 |
|
|||||
News | - | ||||||
Day High | 5.67 | Low High |
|||||
Day Low | 5.59 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Kamada Ltd | KMDA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
5.61 | 5.59 | 5.67 | 5.61 | 5.60 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
149 | 13,869 | $ 5.64 | $ 78,176 | - | 4.08 - 6.5291 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:00:00 | 1,406 | $ 5.61 | USD |
Kamada Ltd Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
324.15M | 57.47M | - | 142.52M | 8.28M | 0.14 | 39.14 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Kamada News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KMDA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 5.91 | 5.91 | 5.57 | 5.70 | 17,644 | -0.30 | -5.08% |
1 Month | 6.37 | 6.5291 | 5.56 | 5.95 | 27,651 | -0.76 | -11.93% |
3 Months | 6.12 | 6.5291 | 5.56 | 5.93 | 23,714 | -0.51 | -8.33% |
6 Months | 5.19 | 6.5291 | 4.08 | 5.68 | 45,456 | 0.42 | 8.09% |
1 Year | 4.60 | 6.5291 | 4.08 | 5.48 | 38,211 | 1.01 | 21.96% |
3 Years | 6.06 | 6.96 | 3.721 | 5.46 | 41,882 | -0.45 | -7.43% |
5 Years | 5.78 | 13.33 | 3.721 | 7.30 | 87,659 | -0.17 | -2.94% |
Kamada Description
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics. |